PureTech and its Founded Entities collaborate with an extensive network of scientists, clinicians and industry leaders, which has enabled us to consistently gain early access to discoveries well before the rest of the world reads about them and resulting in contributions to over 30 publications in top-tier science journals.
PureTech and its Founded Entities collaborate with an extensive network of scientists, clinicians and industry leaders, which has enabled us to consistently gain early access to discoveries well before the rest of the world reads about them and resulting in contributions to over 30 publications in top-tier science journals.

Bill Bradford

Former SVP InterMune; developed pirfenidone for the treatment of IPF

Vincent Cottin

Professor at Université Claude Bernard Lyon; Coordinator of Center for Rare Pulmonary Diseases at Louis Pradel Hospital; Section Editor of the European Respiratory Journal

Kevin Flaherty

Professor at University of Michigan; PhIII trial of nintedanib in pfILD (NEJM)

Toby Maher

Professor & Director of ILD at Keck School of Medicine, USC; PhII trial of pirfenidone in uILDs (Lancet RM)

Paul Noble

Chair, Department of Medicine, Cedars-Sinai; results of two late-stage studies evaluating the effect of pirfenidone in patients w/ IPF (Lancet)

Marlies Wijsenbeek

Chair of Erasmus Medical Center ILD program; PI on study to identify disease progression in patients with newly diagnosed pfILDs

Michael A. Rogawski, MD, PhD

Professor of neurology and pharmacology at the University of California Davis

Steven Paul, MD

Founder and Chair of the Board of Directors at Seaport Therapeutics

Stephen Brannan, MD

Neuroscience drug development expert, former Chief Medical Officer at Karuna Therapeutics (acquired by Bristol Myers Squibb)

Murray Stein, MD, MPH, FRCPC

Distinguished Professor of Psychiatry and Public Health, UC San Diego

Samantha Meltzer-Brody, MD

Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill

Julien Epps, PhD

Associate Professor in Signal Processing with the School of Electrical Engineering and Telecommunications at UNSW Australia

Maurizio Fava, MD

Executive Vice Chair of the Department of Psychiatry; Executive Director of the Massachusetts General Hospital Clinical Trials Network & Institute

B. Brett Finlay, PhD

Howard Hughes Medical Institute Investigator; Professor at the University of British Columbia

Adam Gazzaley, MD, PhD

Founding Director of the Neuroscience Imaging Center at the University of California, San Francisco

Kenya Honda, MD, PhD

Associate Professor of Immunology at the Graduate School of Medicine at the University of Tokyo

H. Robert Horvitz, PhD

David H. Koch Professor of Biology at Massachusetts Institute of Technology, Howard Hughes Medical Institute Investigator, and Neurobiologist (Neurology) at Massachusetts General Hospital

Dan Littman, MD, PhD

Howard Hughes Medical Institute Investigator, Professor of Molecular Immunology and Professor of Pathology and Microbiology at the NYU School of Medicine, member of the Board of Director's at Pfizer

Ruslan Medzhitov, PhD

Howard Hughes Medical Institute Investigator; David W. Wallace Professor of Immunobiology at Yale University School of Medicine

Siddhartha Mukherjee, MD, PhD

Assistant Professor of Medicine at Columbia University; Pulitzer Prize-winning author of Emperor of all Maladies

Christopher Porter, PhD

Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Australia

Alexander Rudensky, PhD

Howard Hughes Medical Institute Investigator, Tri-Institutional Professor at Memorial Sloan-Kettering Cancer Center, the Rockefeller University and Cornell University

Maryanne Senna, MD

Board-Certified Dermatologist at Massachusetts General Hospital and Assistant Professor of Dermatology at Harvard Medical School; Founder and Co-Director of MGH Hair Loss Clinic